Form 4: Boston Scientific EVP John Bradley Sorenson Executes Stock Option and Sells Shares

Executive Vice President of Global Operations at Boston Scientific, John Bradley Sorenson, exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• On May 1, 2024, John Bradley Sorenson, EVP of Global Operations at Boston Scientific, exercised stock options to acquire 17,587 shares of common stock at a price of $17.26 per share.
• Simultaneously, Sorenson sold 17,587 shares of Boston Scientific common stock at a weighted average price of $71.501 per share, with individual sales ranging from $71.201 to $71.83.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.
• Following these transactions, Sorenson directly owns 50,638 shares of Boston Scientific common stock.
• Sorenson also holds options to purchase shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common in publicly traded companies and are often scrutinized by investors to gauge management's confidence in the company's future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including competitors like Medtronic and Abbott Laboratories, to manage their stock holdings in a compliant manner.
• The vesting schedule of the stock options is typical for executive compensation packages.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-planned nature of the transactions mitigates concerns.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates